52 results
Study CKJX839C12301 (ORION-16) is a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in adolescents (aged 12 to <18 years) with HeFH and LDL-C >130 mg/dL (3.4 mmol/L). The use of inclisiran…
The trial will compare two doses of BI 685509 (2 mg and 3 mg BID) with placebo, on top of standard of care, in patients with CSPH in compensated alcohol-related cirrhosis. The primary objective is to estimate the mean difference between treatment…
To evaluate the efficacy and dose-response relationship of XXB750 30 mg SC q4w, 60 mg SC q4w, 120 mg SC q4w, and 240 mg SC q4w compared to placebo in reducing the mean 24hr ambulatory systolic blood pressure (mean 24hr SBP) from baseline to Week 12.…
This study has been transitioned to CTIS with ID 2023-510257-42-01 check the CTIS register for the current data. Sodium-glucose cotransporter 2 (SGLT2) inhibitors lead to a lowering of blood pressure and confer cardiovascular and renal protection in…
The primary objective of this study is to assess the effect of oral butyrate on blood pressure. Secondary objectives are to assess the effect of oral butyrate on faecal and plasma SCFA levels, gut microbiome composition, diuresis, renin and…
The primary objective of the study is to demonstrate the BP lowering effect ofaprocitentan when added to standard-of-care in true resistant hypertension subjects.The secondary objectives of the study are• to demonstrate that the effect of…
Test the effect of five different sodium- and potassium salts in patients with chronic kidney disease.
Primary objectives:1. Is plasma aldosterone concentration associated with microvascular function, specifically insulin-mediated capillary recruitment, in obese subjects?2. Does mineralocorticoid receptor antagonism result in improvement of…
To determine the safety of the MobiusHD System and the efficacy of the MobiusHD device in lowering mean systolic 24-hour ambulatory blood pressure in subjects with resistant hypertension. The hypothesis is that mean systolic 24-hour ambulatory blood…
To determine the safety of the MobiusHD System and the efficacy of the MobiusHD device in lowering mean systolic 24-hour ambulatory blood pressure in subjects with resistant hypertension. The hypothesis is that mean systolic 24-hour ambulatory blood…
To evaluate the safety and effectiveness of the BackBeat Moderato system.
The primary objective of this study is to determine whether daily oral supplementation of Vitamin K2 will slow down or arrest CAC-progression after 12 and 24 months in comparison to placebo in patients with established CAC. Secondary, we wish to…